Bladder cancer: risk factors, emerging treatment strategies and challenges
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
New York
Nova Science
[2014]
|
| Schriftenreihe: | Nova biomedical
Cancer etiology, diagnosis, and treatments |
| Schlagworte: | |
| Beschreibung: | Print version record |
| Beschreibung: | 1 online resource |
| ISBN: | 9781633216709 1633216705 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV044358591 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 170620s2014 |||| o||u| ||||||eng d | ||
| 020 | |a 9781633216709 |9 978-1-63321-670-9 | ||
| 020 | |a 1633216705 |9 1-63321-670-5 | ||
| 035 | |a (ZDB-4-NLEBK)ocn890934182 | ||
| 035 | |a (OCoLC)890934182 | ||
| 035 | |a (DE-599)BVBBV044358591 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 616.62 |2 23 | |
| 245 | 1 | 0 | |a Bladder cancer |b risk factors, emerging treatment strategies and challenges |c Samantha Haggerty, editor |
| 264 | 1 | |a New York |b Nova Science |c [2014] | |
| 264 | 4 | |c © 2014 | |
| 300 | |a 1 online resource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Nova biomedical | |
| 490 | 0 | |a Cancer etiology, diagnosis, and treatments | |
| 500 | |a Print version record | ||
| 505 | 8 | |a Bladder cancer is the fifth most common form of cancer worldwide and is mainly prevalent in developed countries. It is thought to arise through two distinct pathways: the noninvasive and the invasive. The noninvasive pathway gives rise to a superficial papillary carcinoma that is characterized by activating mutations in oncogenes such as H-ras, FGFR3 and PI3K. This pathway is rarely lethal as superficial papillary carcinomas can be readily removed through transurethral resection. However, 15% of noninvasive urothelial tumors can transform into invasive carcinomas and have high recurrence (80% | |
| 650 | 7 | |a HEALTH & FITNESS / Diseases / General |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Clinical Medicine |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Diseases |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Evidence-Based Medicine |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Internal Medicine |2 bisacsh | |
| 650 | 7 | |a Bladder / Cancer |2 fast | |
| 650 | 4 | |a Bladder / Cancer / Treatment | |
| 650 | 4 | |a Bladder / Cancer | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Evidenz-basierte Medizin | |
| 650 | 4 | |a Innere Medizin | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Bladder |x Cancer | |
| 700 | 1 | |a Haggerty, Samantha |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |t Bladder cancer |z 1633216667 |
| 912 | |a ZDB-4-NLEBK | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029761222 | ||
Datensatz im Suchindex
| _version_ | 1804177604488462336 |
|---|---|
| any_adam_object | |
| author2 | Haggerty, Samantha |
| author2_role | edt |
| author2_variant | s h sh |
| author_facet | Haggerty, Samantha |
| building | Verbundindex |
| bvnumber | BV044358591 |
| collection | ZDB-4-NLEBK |
| contents | Bladder cancer is the fifth most common form of cancer worldwide and is mainly prevalent in developed countries. It is thought to arise through two distinct pathways: the noninvasive and the invasive. The noninvasive pathway gives rise to a superficial papillary carcinoma that is characterized by activating mutations in oncogenes such as H-ras, FGFR3 and PI3K. This pathway is rarely lethal as superficial papillary carcinomas can be readily removed through transurethral resection. However, 15% of noninvasive urothelial tumors can transform into invasive carcinomas and have high recurrence (80% |
| ctrlnum | (ZDB-4-NLEBK)ocn890934182 (OCoLC)890934182 (DE-599)BVBBV044358591 |
| dewey-full | 616.62 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.62 |
| dewey-search | 616.62 |
| dewey-sort | 3616.62 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02260nmm a2200517zc 4500</leader><controlfield tag="001">BV044358591</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">170620s2014 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781633216709</subfield><subfield code="9">978-1-63321-670-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1633216705</subfield><subfield code="9">1-63321-670-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-4-NLEBK)ocn890934182</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)890934182</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044358591</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.62</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Bladder cancer</subfield><subfield code="b">risk factors, emerging treatment strategies and challenges</subfield><subfield code="c">Samantha Haggerty, editor</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York</subfield><subfield code="b">Nova Science</subfield><subfield code="c">[2014]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Nova biomedical</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Cancer etiology, diagnosis, and treatments</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Print version record</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Bladder cancer is the fifth most common form of cancer worldwide and is mainly prevalent in developed countries. It is thought to arise through two distinct pathways: the noninvasive and the invasive. The noninvasive pathway gives rise to a superficial papillary carcinoma that is characterized by activating mutations in oncogenes such as H-ras, FGFR3 and PI3K. This pathway is rarely lethal as superficial papillary carcinomas can be readily removed through transurethral resection. However, 15% of noninvasive urothelial tumors can transform into invasive carcinomas and have high recurrence (80%</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS / Diseases / General</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Clinical Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Diseases</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Evidence-Based Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Internal Medicine</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bladder / Cancer</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bladder / Cancer / Treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bladder / Cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Evidenz-basierte Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Innere Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bladder</subfield><subfield code="x">Cancer</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haggerty, Samantha</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="t">Bladder cancer</subfield><subfield code="z">1633216667</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-NLEBK</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029761222</subfield></datafield></record></collection> |
| id | DE-604.BV044358591 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:50:43Z |
| institution | BVB |
| isbn | 9781633216709 1633216705 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029761222 |
| oclc_num | 890934182 |
| open_access_boolean | |
| physical | 1 online resource |
| psigel | ZDB-4-NLEBK |
| publishDate | 2014 |
| publishDateSearch | 2014 |
| publishDateSort | 2014 |
| publisher | Nova Science |
| record_format | marc |
| series2 | Nova biomedical Cancer etiology, diagnosis, and treatments |
| spelling | Bladder cancer risk factors, emerging treatment strategies and challenges Samantha Haggerty, editor New York Nova Science [2014] © 2014 1 online resource txt rdacontent c rdamedia cr rdacarrier Nova biomedical Cancer etiology, diagnosis, and treatments Print version record Bladder cancer is the fifth most common form of cancer worldwide and is mainly prevalent in developed countries. It is thought to arise through two distinct pathways: the noninvasive and the invasive. The noninvasive pathway gives rise to a superficial papillary carcinoma that is characterized by activating mutations in oncogenes such as H-ras, FGFR3 and PI3K. This pathway is rarely lethal as superficial papillary carcinomas can be readily removed through transurethral resection. However, 15% of noninvasive urothelial tumors can transform into invasive carcinomas and have high recurrence (80% HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh Bladder / Cancer fast Bladder / Cancer / Treatment Bladder / Cancer Cancer Evidenz-basierte Medizin Innere Medizin Medizin Bladder Cancer Haggerty, Samantha edt Erscheint auch als Druck-Ausgabe Bladder cancer 1633216667 |
| spellingShingle | Bladder cancer risk factors, emerging treatment strategies and challenges Bladder cancer is the fifth most common form of cancer worldwide and is mainly prevalent in developed countries. It is thought to arise through two distinct pathways: the noninvasive and the invasive. The noninvasive pathway gives rise to a superficial papillary carcinoma that is characterized by activating mutations in oncogenes such as H-ras, FGFR3 and PI3K. This pathway is rarely lethal as superficial papillary carcinomas can be readily removed through transurethral resection. However, 15% of noninvasive urothelial tumors can transform into invasive carcinomas and have high recurrence (80% HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh Bladder / Cancer fast Bladder / Cancer / Treatment Bladder / Cancer Cancer Evidenz-basierte Medizin Innere Medizin Medizin Bladder Cancer |
| title | Bladder cancer risk factors, emerging treatment strategies and challenges |
| title_auth | Bladder cancer risk factors, emerging treatment strategies and challenges |
| title_exact_search | Bladder cancer risk factors, emerging treatment strategies and challenges |
| title_full | Bladder cancer risk factors, emerging treatment strategies and challenges Samantha Haggerty, editor |
| title_fullStr | Bladder cancer risk factors, emerging treatment strategies and challenges Samantha Haggerty, editor |
| title_full_unstemmed | Bladder cancer risk factors, emerging treatment strategies and challenges Samantha Haggerty, editor |
| title_short | Bladder cancer |
| title_sort | bladder cancer risk factors emerging treatment strategies and challenges |
| title_sub | risk factors, emerging treatment strategies and challenges |
| topic | HEALTH & FITNESS / Diseases / General bisacsh MEDICAL / Clinical Medicine bisacsh MEDICAL / Diseases bisacsh MEDICAL / Evidence-Based Medicine bisacsh MEDICAL / Internal Medicine bisacsh Bladder / Cancer fast Bladder / Cancer / Treatment Bladder / Cancer Cancer Evidenz-basierte Medizin Innere Medizin Medizin Bladder Cancer |
| topic_facet | HEALTH & FITNESS / Diseases / General MEDICAL / Clinical Medicine MEDICAL / Diseases MEDICAL / Evidence-Based Medicine MEDICAL / Internal Medicine Bladder / Cancer Bladder / Cancer / Treatment Cancer Evidenz-basierte Medizin Innere Medizin Medizin Bladder Cancer |
| work_keys_str_mv | AT haggertysamantha bladdercancerriskfactorsemergingtreatmentstrategiesandchallenges |